Theranostics in Pediatric Cancer: New Integrated Research Center Aims to Transform Childhood Cancer Treatment

What Is Theranostics and Why Does It Matter for Cancer Treatment?

Theranostics is a rapidly emerging field in precision oncology that pairs diagnostic imaging with targeted radioligand therapy. The approach uses radiopharmaceuticals — molecules that combine a targeting agent with a radioactive isotope — to first locate cancer cells through imaging (the diagnostic component) and then deliver radiation directly to those cells (the therapeutic component). This "see it and treat it" strategy allows for highly personalized treatment plans based on each patient's tumor biology.

The partnership between the University of Kansas Health System, University of Kansas Medical Center, Children's Mercy, and BAMF Health represents a significant investment in building a fully integrated destination center for theranostic research and treatment. BAMF Health has been a notable player in expanding access to theranostics across the United States. The collaboration is expected to combine the pediatric expertise of Children's Mercy with the research infrastructure of the University of Kansas system and BAMF Health's theranostic manufacturing and delivery capabilities.

Currently, the FDA has approved two major theranostic radiopharmaceuticals: lutetium Lu-177 dotatate (Lutathera) for gastroenteropancreatic neuroendocrine tumors and lutetium Lu-177 vipivotide tetraxetan (Pluvicto) for metastatic castration-resistant prostate cancer. However, dozens of clinical trials are exploring theranostic approaches for other cancer types, including pediatric tumors such as neuroblastoma.

How Could Theranostics Improve Outcomes for Children With Cancer?

Pediatric oncology faces a unique challenge: while survival rates for childhood cancers have improved dramatically over the past several decades — with five-year survival now exceeding 80% for many types according to the National Cancer Institute — many survivors face serious long-term health consequences from conventional treatments including chemotherapy and external beam radiation. These late effects can include secondary cancers, organ damage, growth impairment, and neurocognitive deficits, making less toxic treatment alternatives especially valuable for young patients.

Theranostic approaches are being investigated for several childhood cancers. Meta-iodobenzylguanidine (MIBG) therapy, which targets neuroblastoma cells, has been used in pediatric oncology for years and represents an early form of theranostic treatment. Newer approaches using lutetium-177 and actinium-225 labeled agents are being studied in clinical trials for various pediatric solid tumors. The integrated center model — combining research, manufacturing, and clinical treatment under a coordinated partnership — could accelerate the development and availability of these therapies for children.

The involvement of Children's Mercy, one of the nation's leading pediatric hospitals, suggests a strong focus on developing and validating theranostic protocols specifically designed for pediatric patients, where dosing, safety profiles, and long-term follow-up requirements differ significantly from adult oncology.

What Does This Mean for the Future of Radiopharmaceutical Medicine?

One of the major barriers to wider adoption of theranostics has been the limited infrastructure for manufacturing and delivering radiopharmaceuticals, which often have short half-lives and require specialized facilities. According to the Society of Nuclear Medicine and Molecular Imaging, demand for theranostic treatments has grown substantially, but access remains concentrated at a relatively small number of specialized centers. The Kansas partnership's emphasis on building a "fully integrated" facility addresses this bottleneck directly by co-locating research, radiopharmaceutical production, and clinical treatment.

The radiopharmaceutical sector has attracted significant pharmaceutical industry investment in recent years, with major acquisitions including Novartis's purchase of Advanced Accelerator Applications (which developed Lutathera) and Bristol Myers Squibb's acquisition of RayzeBio. The global theranostics market is projected to grow substantially through the end of the decade, driven by expanding indications and new radioisotope-drug combinations entering clinical trials. Centers like the one being developed in Kansas could help bridge the gap between clinical research and patient access, particularly for pediatric populations that have historically been underrepresented in radiopharmaceutical trials.